Parkinson’s Disease Related Content

Clinical Trial Tests Novel Stem-Cell Treatment for Parkinson’s Disease

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson’s disease in which a patient’s stem cells are reprogrammed to replace dopamine cells in the brain damaged by the disease. The first-of-its...

Personalizing Stem Cell Therapy for Parkinson’s Disease

In the United States alone, as many as one million people have Parkinson’s disease (PD), with approximately 60,000 cases being diagnosed each year, according to the Parkinson’s Disease Foundation. Kwang-Soo Kim, PhD, director of the Molecular Neurobiology Laboratory at McLean Hospital and professor...

New Possibilities for Parkinson’s Disease

A team of investigators from McLean Hospital and Massachusetts General Hospital (MGH) reported that reprogramming a patient’s own skin cells to replace cells in the brain that are progressively lost during Parkinson’s disease (PD) is technically feasible. PD is the second most common...

Staff Profile: Kwang-Soo Kim, PhD

Kwang-Soo Kim, PhD, has over 35 years of experience investigating molecular and developmental neurobiology of the midbrain dopamine neuronal system in health and disease, focusing on elucidating transcriptional mechanisms underlying development and maintenance of dopamine neurons. Based on basic...

Staff Profile: Pierre R. Leblanc, PhD

Pierre R. Leblanc, PhD, received his BSc in Biochemistry from McGill University and his PhD in Biochemistry from McMaster University, studying membranes biogenesis. He performed his post-doctoral work at the Massachusetts Institute of Technology, focusing on the gamma/delta T-cell receptor...

Staff Profile: Kai-Christian Sonntag, MD, PhD

As a graduate of University of Heidelberg Medical School, Dr. Sonntag studied the molecular biology of viruses, and as a research fellow at the Transplantation Biology Research Center at Massachusetts General Hospital, he conducted research in transplantation immunology. In 2000, he joined McLean...

Staff Profile: Teresia Osborn, PhD

Teresia Osborn, PhD, graduated from Gothenburg University with a MS in pharmaceutical bioscience in 2002 and a PhD in leukocyte biology in 2007. Throughout her graduate studies she was also a research fellow at the Division of Translational Medicine at Brigham and Women’s Hospital. She joined the...

Staff Profile: Sivan Subburaju, PhD

Dr. Sivan Subburaju obtained his PhDs in neurobiology and neuroendocrinology, respectively, from the University of Madras and the National University of Singapore. He completed his visiting research fellow training at the National Institute of Child Health and Development, Bethesda in 2007 and...

Staff Profile: Ole Isacson, Dr Med Sci

Dr. Ole Isacson is a professor of neurology at Harvard Medical School and founding director of the Neuroregeneration Research Institute at McLean Hospital. His work is focused on the understanding and treatments of neurodegenerative disease, with particular emphasis on distinguishing critical...

Staff Profile: Penny Hallett, PhD

Penny Hallett, PhD, is an associate professor of psychiatry at Harvard Medical School and co-director of the Neuroregeneration Research Institute (NRI). She received her PhD from the University of Manchester, UK, and completed post-doctoral studies at Massachusetts General Hospital, moving in 2006...

Staff Profile: Woori Kim, PhD

Woori Kim, PhD, received her BSc, MSc, and PhD in biochemistry from Hanyang University. She joined the Molecular Neurobiology Laboratory in 2014 as a post-doctoral fellow and is now an investigator.

Staff Profile: Frank I. Tarazi, MBBS, PhD, EMBA

Frank I. Tarazi, MBBS, PhD, EMBA, is a preclinical and clinical expert in the diagnosis and treatment of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, schizophrenia, bipolar disorder, depression, and ADHD. He has published over 140 articles and reviews in highly cited...